CN103037898B - 呼吸道合胞病毒抗原组合物和方法 - Google Patents

呼吸道合胞病毒抗原组合物和方法 Download PDF

Info

Publication number
CN103037898B
CN103037898B CN201180033742.9A CN201180033742A CN103037898B CN 103037898 B CN103037898 B CN 103037898B CN 201180033742 A CN201180033742 A CN 201180033742A CN 103037898 B CN103037898 B CN 103037898B
Authority
CN
China
Prior art keywords
rsv
polypeptide
epitope
designed
polyelectrolyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180033742.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103037898A (zh
Inventor
托马斯·J·鲍威尔
詹姆斯·戈勒姆·博伊德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artificial Cell Technologies Inc
Original Assignee
Artificial Cell Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artificial Cell Technologies Inc filed Critical Artificial Cell Technologies Inc
Priority to CN201610369657.4A priority Critical patent/CN106008716B/zh
Publication of CN103037898A publication Critical patent/CN103037898A/zh
Application granted granted Critical
Publication of CN103037898B publication Critical patent/CN103037898B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201180033742.9A 2010-07-07 2011-07-07 呼吸道合胞病毒抗原组合物和方法 Active CN103037898B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610369657.4A CN106008716B (zh) 2010-07-07 2011-07-07 呼吸道合胞病毒抗原组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36202910P 2010-07-07 2010-07-07
US61/362,029 2010-07-07
US201161485669P 2011-05-13 2011-05-13
US61/485,669 2011-05-13
PCT/US2011/043136 WO2012006395A1 (en) 2010-07-07 2011-07-07 Respiratory syncytial virus antigenic compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610369657.4A Division CN106008716B (zh) 2010-07-07 2011-07-07 呼吸道合胞病毒抗原组合物和方法

Publications (2)

Publication Number Publication Date
CN103037898A CN103037898A (zh) 2013-04-10
CN103037898B true CN103037898B (zh) 2016-06-29

Family

ID=45438747

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180033742.9A Active CN103037898B (zh) 2010-07-07 2011-07-07 呼吸道合胞病毒抗原组合物和方法
CN201610369657.4A Active CN106008716B (zh) 2010-07-07 2011-07-07 呼吸道合胞病毒抗原组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610369657.4A Active CN106008716B (zh) 2010-07-07 2011-07-07 呼吸道合胞病毒抗原组合物和方法

Country Status (13)

Country Link
US (1) US9487593B2 (https=)
EP (1) EP2590675B1 (https=)
JP (1) JP5890407B2 (https=)
CN (2) CN103037898B (https=)
AU (1) AU2011276251B2 (https=)
BR (1) BR112013000345B1 (https=)
CA (1) CA2799934C (https=)
DK (1) DK2590675T3 (https=)
ES (1) ES2688993T3 (https=)
IL (1) IL222723B (https=)
MX (1) MX340796B (https=)
RU (1) RU2609661C2 (https=)
WO (1) WO2012006395A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9433671B2 (en) 2012-03-30 2016-09-06 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US8883717B2 (en) * 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods
MY171498A (en) 2012-08-01 2019-10-15 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
IL292567B2 (en) 2013-08-13 2025-06-01 Univ Northwestern Peptide conjugated particles
WO2015183716A1 (en) 2014-05-27 2015-12-03 Artificial Cell Technologies, Inc. Automated layer by layer construction of multilayer coated cores by tff
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2017048689A1 (en) 2015-09-16 2017-03-23 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US20170230649A1 (en) * 2016-02-05 2017-08-10 Qualcomm Incorporated Calibration of hybrid auto focus (af) imaging systems
KR102774312B1 (ko) 2017-04-04 2025-03-05 유니버시티 오브 워싱톤 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도
CA3079604A1 (en) 2017-10-13 2019-04-18 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus g protein central conserved region
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
EP3833677A4 (en) 2018-08-08 2022-04-27 Trellis Bioscience, Inc. IMPROVED RSV PASSIVE AND ACTIVE VACCINES
US20230414526A1 (en) * 2022-03-29 2023-12-28 Artificial Cell Technologies, Inc. Respiratory syncytial virus antigenic compositions and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108226A1 (en) * 2005-04-12 2006-10-19 The University Of Queensland Vaccine delivery system
WO2009079066A2 (en) * 2007-09-26 2009-06-25 Aparna Biosciences Therapeutic and vaccine polyelectrolyte nanoparticle compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2142817C1 (ru) * 1993-08-06 1999-12-20 Коннот Лабораториз Лимитед Инактивированные вакцины респираторно-синцитиального вируса
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ATE178906T1 (de) 1994-08-25 1999-04-15 Stichting Inst Dierhouderij Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv- infektionen
FR2726471B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
DE60136381D1 (de) 2000-10-18 2008-12-11 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
AUPR520201A0 (en) 2001-05-23 2001-06-14 Commonwealth Scientific And Industrial Research Organisation Antiviral compounds
JP3997930B2 (ja) 2003-02-27 2007-10-24 富士ゼロックス株式会社 カーボンナノチューブの製造装置および製造方法
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
US7615530B2 (en) 2003-08-29 2009-11-10 Artificial Cell Technologies, Inc. Immunogenic compositions and methods of use
US7348399B2 (en) * 2003-08-29 2008-03-25 Louisiana Tech University Foundation, Inc. Nanofabricated polypeptide multilayer films, coatings, and microcapsules
WO2006023029A2 (en) * 2004-06-16 2006-03-02 The Johns Hopkins University The cysteine-rich region of respiratory syncytial virus and methods of use therefor
US20080131450A1 (en) 2004-07-23 2008-06-05 Pierre Fabre Medicament Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions
US20080171070A1 (en) * 2005-01-31 2008-07-17 Pierre Schaaf Polyelectrolyte Multilayer Film, Preparation And Uses Thereof
CA2627376C (en) * 2005-10-25 2016-07-05 Donald Templeton Haynie Immunogenic compositions and methods of use
EP1972348A1 (en) 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
JP2010522540A (ja) 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
US7723294B2 (en) * 2007-04-02 2010-05-25 Artificial Cell Technologies, Inc. Polypeptide films and methods
EP2058002A1 (en) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
MX2011000668A (es) 2008-07-18 2011-07-29 Id Biomedical Corp Quebec Antigenos quimericos polipeptidicos del virus sincitial respiratorio.
US20110318376A1 (en) 2008-12-24 2011-12-29 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
US8883717B2 (en) * 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108226A1 (en) * 2005-04-12 2006-10-19 The University Of Queensland Vaccine delivery system
WO2009079066A2 (en) * 2007-09-26 2009-06-25 Aparna Biosciences Therapeutic and vaccine polyelectrolyte nanoparticle compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Layer-by-layer-assembled multilayer films for transcutaneous drug and vaccine delivery";Xingfang Su et al.;《ACS NANO》;20091124;第3卷(第11期);第3719页摘要和左栏第1段 *
"Multilayered polyelectrolyte films: from active molecular delivery to vaccine therapy";Jean-Claude Voegel;《ACS NANO》;20091124;第3卷(第11期);第3343页摘要，左栏第1段，第3345页中间栏第1段，以及第3345页中间栏和右栏的引证文件8和15 *
"Respiratory syncytial virus vaccine development";Yoshihiko Murata;《Clinics in Laboratory Medicine》;20091231;第29卷(第4期);第6页第3段 *
A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules";Siow Feng Chong et al.;《Biomaterials》;20090709;第30卷(第28期);第5178页摘要 *

Also Published As

Publication number Publication date
WO2012006395A1 (en) 2012-01-12
MX340796B (es) 2016-07-27
DK2590675T3 (en) 2018-10-29
US20120009254A1 (en) 2012-01-12
AU2011276251B2 (en) 2015-02-05
EP2590675A1 (en) 2013-05-15
CA2799934A1 (en) 2012-01-12
MX2012015030A (es) 2013-06-13
CA2799934C (en) 2020-01-28
CN106008716B (zh) 2019-08-13
IL222723A0 (en) 2012-12-31
JP5890407B2 (ja) 2016-03-22
US9487593B2 (en) 2016-11-08
RU2609661C2 (ru) 2017-02-02
AU2011276251A1 (en) 2012-11-08
IL222723B (en) 2020-03-31
CN106008716A (zh) 2016-10-12
BR112013000345A2 (pt) 2016-05-31
ES2688993T3 (es) 2018-11-07
EP2590675B1 (en) 2018-08-29
BR112013000345B1 (pt) 2021-11-23
CN103037898A (zh) 2013-04-10
JP2013535428A (ja) 2013-09-12
RU2013101972A (ru) 2014-08-20
AU2011276251A2 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
CN103037898B (zh) 呼吸道合胞病毒抗原组合物和方法
EP2308900B1 (en) Immunogenic compositions and methods of use
CN104244971B (zh) 抗疟疾微颗粒疫苗
CN104220089B (zh) 抗原性组合物和方法
JP6934862B2 (ja) 抗マラリア組成物および方法
US20220096617A1 (en) Anti-malaria compositions and methods
JP2025510345A (ja) 呼吸器合成ウイルス抗原組成物および方法
HK1254028B (zh) 抗疟疾组合物和方法
HK1206972B (en) Microparticle/nanoparticle vaccine against malaria

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant